Collaborating with outstanding researchers, academic institutions, entrepreneurs and leaders in the biotech and pharma industry, we provide capital, network and know-how to transform promising life-science discoveries into successful biotech startups.
With this platform, we strive to be the preferred early-stage investor and partner of the European life science industry.
Covering the spectrum from early-stage discoveries to clinical-stage companies, we focus on two main areas:
- Company creation and building biotech startups in the Nordic region.
- Early-stage investments in promising biotech and medtech companies in the rest of Europe.
We aim to develop strong and competitive companies that we finance all the way to a commercial exit.
In 2016, we invested about DKK 150 million in new companies, and we currently have 18 active portfolio companies. In the coming years, we will continue to increase our investments activities in both the Nordics and other parts of Europe.